B
MXCT icon

Bailard’s MaxCyte MXCT Stock Holding History

Bailard’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,800
Closed -$232K – 782
2021
Q4 		$232K Buy
+22,800
New +$245K 0.01% 635

Other funds holding MXCT

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bailard's MXCT Position: Q1 2022 in Review

Bailard sold out of MaxCyte (MXCT) in Q1 2022, closing a stake of 22,800 shares — an estimated $232K sold.

Bailard first reported a position in MXCT in Q4 2021 and held it in 1 quarter. The position peaked at $232K in Q4 2021. 98 funds tracked by Wall St. Rank hold MXCT as of Q1 2022.

  • Bailard reported no remaining MaxCyte position as of Q1 2022 after selling out during the quarter.
  • Bailard sold 22,800 MaxCyte shares in Q1 2022, an estimated $232K.
  • Bailard first reported a position in MaxCyte in Q4 2021 and held it in 1 quarter.
  • Bailard's MaxCyte position peaked at $232K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held MaxCyte as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.